GlassScriptPhysician profile
Witold Anthony Turkiewicz
NPI 1972584027
$15,878.77
in general payments reported to CMS, 2019-2025
36 companies · $2,902 in 2025
The $2,902 reported for 2025 was more than what 76% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,963 · 2020: $1,444 · 2021: $1,443 · 2022: $1,408 · 2023: $2,362 · 2024: $3,356 · 2025: $2,902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,680 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $750 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,679.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $750.00 |
| Education | $191.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,103.11 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $2,756.69 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $1,667.42 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $989.40 | 2019-2025 | |
| Janssen Biotech, INC. | $858.89 | 2019-2025 | Tremfya |
| Ucb, INC. | $761.55 | 2019-2025 | Bimzelx, Cimzia |
| Radius Health, INC. | $633.74 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $520.85 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $493.08 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $487.99 | 2020-2025 | Ofev, Cyltezo, Jascayd |
| Lilly USA, LLC | $396.11 | 2019-2024 | Taltz |
| Glaxosmithkline, LLC. | $390.13 | 2019-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $390.13 | 2021-2025 | Acthar |
| Genentech USA, INC. | $375.68 | 2019-2025 | Actemra, Gazyva |
| Aurinia Pharma U.S., INC. | $272.09 | 2021-2025 | Lupkynis |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $268.47 | 2023-2025 | Idacio |
| Ani Pharmaceuticals, INC. | $244.22 | 2023-2025 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $197.37 | 2019 | |
| Organon LLC | $113.47 | 2023-2025 | Hadlima, Renflexis, Nexplanon |
| Alexion Pharmaceuticals, INC. | $110.62 | 2019-2024 | Strensiq |
| Sandoz INC. | $109.71 | 2023-2025 | Hyrimoz |
| Horizon Therapeutics Plc | $107.42 | 2019-2023 | Krystexxa |
| Celgene Corporation | $101.46 | 2019 | |
| Bioventus LLC | $87.31 | 2019-2021 | |
| Fidia Pharma USA INC. | $72.84 | 2019-2023 | Hymovis |
| Ferring Pharmaceuticals INC. | $59.03 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $45.15 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $44.54 | 2020 | |
| Genzyme Corporation | $43.01 | 2020-2023 | |
| Genentech, INC. | $39.95 | 2019 | |
| Merck Sharp & Dohme LLC | $37.22 | 2019-2020 | |
| Sobi, INC | $26.47 | 2019 | |
| Almatica Pharma LLC | $22.32 | 2025 | Teriparatide |
| Pharming Healthcare, INC. | $21.18 | 2024 | Ruconest |
| Pacira Therapeutics, INC. | $18.01 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Witold Turkiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.